As cancers grow and metastasize they evoke immune responses in the host. These host responses vary in their nature and effect and, in most instances, are eventually overcome by progressively growing tumour. Nevertheless, they have important implications for prognosis and, perhaps, eventually for treatment.
Primary Tumour
The metastasizing capacity of primary tumours is difficult to assess except in terms of histological differentiation. Non-morphological criteria of metastasizing potential are largely speculative although immunological dedifferentiation and heterogeneity is a definite possibility. Lymphoplasmacytic infiltrates at the growing edge are characteristic of some primary tumours, notably certain seminomas and breast cancers, where their presence is a favourable prognostic feature. They are regarded as evidence of a local host response but their mode of operation is unclear.
Regional Lymph Nodes
Morphological changes in uninvolved local nodes have been studied in the vicinity of cancers of the breast (Black 1965 , Anastassiades & Pryce 1966 , Hamlin 1968 , Alderson et al. 1971 , larynx (Bennett et al. 1971) , stomach (Black et al. 1971) and cervix uteri (Tsakraklides et al. 1973) . Several reactive patterns have been described; in general, reactive changes are favourable prognostic features while inactive or lymphocytedepleted nodes carry a more adverse prognosis. Several questions remain. Do changes in the regional nodes carry the same prognostic weight as host reactions around the primary tumour? Can the changes in the nodes be ranked in order of prognostic significance? And what are their functional implications? Morphology is not wellsuited to answer this last question, and a few investigators have tried other approaches. Immunofluorescence has revealed cell-bound immunoglobulins in local uninvolved nodes (Burtin et al. 1969) . Cells from uninvolved nodes are readily transformed by phytohmemagglutinin (Fisher et al. 1972 ). Other workers have studied cultures of lymph node cells to which tumour cells have been added (Richters & Sherwin 1971 , Deodhar et al. 1972 . Various interactions between tumour cells and lymphoid cells are described but evidence of actual tumour cell destruction is scanty.
Additional information stems from experimental animals in which nodes draining tumours show many of the changes found in man (Carter & Gershon 1966 , 1967 , Carter et al. 1968 . A few recent observations are briefly summarized:
(1) Hyperplasia of the T cell-containing paracortex is frequently observed , Weston et al. 1972 . It occurs early after tumour transplantation and, at its peak, may coincide with a phase of slowed growth in the tumour. The response then declines and the tumour grows progressively. If normally non-metastasizing tumours are transplanted into T cell deficient mice, unable to mount a paracortical response, the local tumour grafts grow progressively and about half of them metastasize (Weston et al. 1974 ).
(2) The time scale of proliferation among paracortical T cells suggests a sequence of stimulation through to anergy. Flannery et al. (1973) found that lymphocytes from nodes draining a transplanted squamous carcinoma in rats were maximally cytotoxic after two weeks. Four weeks later cytotoxicity had waned and metastases appeared. The nature of the cytotoxic cells (T or B) was not established. It is unclear whether the anergic phase is specific. Some workers have reported impaired immune responses in tumourbearing animals challenged with unrelated antigens ), but others have found such responses unchanged (Flannery et al. 1973 ).
(3) Although the immune response to tumours is initially localized in the local nodes, it soon systematizes to other parts of the lymphoid system (Mitchison 1954 ). In the experiments of Flannery et al. (1973) , cytotoxic lymphocytes were eventually demonstrated in distant lymph nodes and spleen after they had appeared in the local nodes. Activity in these remote sites continued after cytotoxicity in the draining nodes had declined. Excision of Uninvolved Regional Lymph Nodes The demonstration of immune reactivity in the draining nodes has therapeutic implications, and controversy continues over the management of uninvolved nodes in some cancers. Much of the argument stems from the work of Crile (1965 Crile ( , 1968 . Baldly summarized, he has shown that excision of small transplanted tumours (allogeneic and syngeneic) together with the local nodes at about ten days is followed by more deleterious effects than removal of the tumour Section ofOncology alone, namely a higher incidence of metastases to other nodes or the lungs, and an increased susceptibility to rechallenge with the same tumour. Several of the investigators who have disputed Crile's findings have tended to remove larger tumours at a later stage after grafting. Timing is critical. The clinical implications of Crile's observations are uncertain; most human cancers grow slowly and it seems improbable that an immune response, even if initiated in the draining nodes, has not systematized by the time the patient first presents.
Involved Nodes
Various consequences follow once tumour cells are retained in the local nodes. Experimental evidence indicates that some will die in situ or lie dormant. Proliferation of tumour cells is the most obvious clinical outcome but proliferation is not invariably progressive. Thus, growth of some axillary node metastases from breast cancers appears to be limited and arrest or regression may perhaps occur (Edwards et al. 1972) .
Hamatogenous Dissemination
Although the demonstration of circulating tumour cells is of no prognostic significance, hematogenous dissemination is of prime importance.
Interaction between tumour cells and circulating immune cells has been widely studied in vitro.
Lymphopenia is common in advanced malignant disease and is an adverse prognostic finding (Riesco 1970) . It may be induced or exacerbated by treatment, notably by radiotherapy, and Stjernsward et al. (1972) have suggested that irradiation selectively depletes T cells. The long-term effects of T cell deficiency have yet to be determined. Cytoxic lymphocytes have been described in vitro in many forms of human cancer (Hellstrdm et al. 1968 , Hellstrdm, Hellstrom, Sjogren & Warner 1971 , Hellstrbm, Sjogren, Warner & Hellstrom 1971 . The literature is now extensive and only one aspect will be discussed here.
The Hellstroms initially found that the incidence of cytotoxic blood lymphocytes was unrelated to the stage of the disease. Subsequent studiesin patients with malignant melanoma, some sarcomas and cancers of the kidney and bladderindicate that in vitro lymphocyte cytotoxicity is demonstrable in the presence of early or localized tumours but is diminished or absent in recurrent or metastatic disease (Hellstrom & Hellstrom 1972 , Currie & Basham 1972 , Perlmann et al. 1972 , Hellstrdm et al. 1973 , Currie 1973 ). Currie & Basham (1972) suggest that the lymphocytes are progressively coated with an inhibitory factor from the serum. This factor is removed after extensive washing and hitherto inactive cells become cytotoxic. Thus, changes in cytotoxicity may reflect the metastasizing potential of a tumour and form the basis for a prognostic test (Hellstrom & Hellstrom 1972 , Currie 1973 .
Immunoglobulins
Specific complement-dependent cytotoxic antibodies have been demonstrated in some patients with malignant melanoma, neuroblastoma and certain sarcomas after the main tumour mass has regressed or been removed (Smith 1972) . After the elimination of a major source of tumour cells and tumour-specific antigens, free cytotoxic antibodies may help to control or eradicate circulating tumour cells or even micrometastases. Similar cytotoxic antibodies are not often found in the commoner tumours though non-cytotoxic antibodies, often of doubtful specificity, may occur. 'Blocking' antibodies have already been noted.
Further Observations on Immunological Factors and Metastasis
There is clinical and experimental evidence that corticosteroids, X-rays, and cytotoxic drugs enhance metastasis. Such observations are, however, no more than suggestive. All the agents noted are immunosuppressants but they exert other, non-immunological effects as well. Furthermore, much of the experimental work is conflicting. A stronger lead comes from studies with antithymocyte serum (ATS) which provokes or increases metastases from several autochthonous and allogeneic tumours in animals (Deodhar & Crile 1969 , Fisher et al. 1969 , Gershon & Carter 1970 . Since ATS primarily affects T cells it is probable that T cells are involved in controlling at least some potentially metastasizing tumours: some normally non-metastasizing tumours will metastasize when transplanted into T-cell-deficient mice (Weston et al. 1974 ).
Three general points may be made: (1) The effects of T-cell-deficiency are far reaching. Besides a deficit in T cells, there will be deficiencies in T-cell-associated products (lymphokines), and possibly defective cooperation between T and B lymphocytes and disorganized B cell activity.' (2) Undue emphasis on T cells may be misleading. The immune response to metastasizing tumour is likely to involve other types of lymphocytes, macrophages and immunoglobulins, all of which 'A recent paper by Woodruff et al. 1973 , shows that the growth rate of some syngeneic tumours in T-cell-deficient mice is not increased; the development of metastases is not described. may interact with tumour cells in different ways, at different times in the course of the disease, in different parts of the body and with different outcomes. (3) Immune reactions to disseminating tumour are likely to vary in different forms of malignant disease. Quite different responses may be anticipated in cancers of the breast, seminomas, melanomas and osteosarcomas. It is accepted that tumours have different etiologies and pathogenesis. Equal diversity is likely in the details of their subsequent metastasis, and in the host's response to them. In most patients with cancer we cannot control the development and growth of metastases. But in a few, most notably those with cancer of the breast, remarkable remissions of the disease may take place when the endocrine environment is altered by administration of hormones or ablation of endocrine glands. When treated in this way fungating lesions of the breast may shrink and heal, lytic lesions of bone recalcify and remodel and leukocrythroblastic blood pictures return to normal. This state of affairs lasts on average for 18 months to 2 years and then the disease progresses again.
Many methods are available by which remission may be achieved. They include a wide range of hormones including androgens, oestrogens, progestogens and corticosteroids and removal or ablation of the ovaries, adrenals and pituitary. In addition radiotherapy and a wide range of cytotoxic drugs may have some part to play. Unfortunately confusion still exists about the indications for and the relative value of the various forms of treatment. In one review (Forrest 1967) most patients were found to have received at least 3 types of treatment and many had received 5 or even more. But the choice of treatments and the order in which they were given varied greatly and seemed to follow no rational plan. This study was carried out in the hope that the results would help towards a rational
